Olson Eric R 4
4 · Syros Pharmaceuticals, Inc. · Filed Feb 19, 2021
Insider Transaction Report
Form 4
Olson Eric R
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2021-02-17+94,000→ 94,000 totalExercise: $11.41Exp: 2031-02-16→ Common Stock (94,000 underlying)
Footnotes (1)
- [F1]This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2022, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter.